First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ecto-domain, with site-specific conjugation to a tubulysin-based microtubule inhibitor payload. MEDI4276 demonstrates enhanced cellular internalization and cytolysis of HER2-positiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Pegram, Mark D., Hamilton, Erika P., Tan, Antoinette R., Storniolo, Anna Maria, Balic, Kemal, Rosenbaum, Anton I., Liang, Meina, He, Peng, Marshall, Shannon, Scheuber, Anita, Das, Mayukh, Patel, Manish R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398097/
https://www.ncbi.nlm.nih.gov/pubmed/34045233
http://dx.doi.org/10.1158/1535-7163.MCT-20-0014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398097/
https://www.ncbi.nlm.nih.gov/pubmed/34045233
http://dx.doi.org/10.1158/1535-7163.MCT-20-0014

Ejemplares similares